These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747 [TBL] [Abstract][Full Text] [Related]
7. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003 [TBL] [Abstract][Full Text] [Related]
8. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225 [TBL] [Abstract][Full Text] [Related]
9. miR-146b measurement in FNA to distinguish papillary thyroid cancer from benign thyroid masses. Yang F; Zhang H; Leng X; Hao F; Wang L Br J Biomed Sci; 2018 Jan; 75(1):43-45. PubMed ID: 28937915 [No Abstract] [Full Text] [Related]
10. miRNA profiling, detection of BRAF V600E mutation and RET-PTC1 translocation in patients from Novosibirsk oblast (Russia) with different types of thyroid tumors. Titov SE; Ivanov MK; Karpinskaya EV; Tsivlikova EV; Shevchenko SP; Veryaskina YA; Akhmerova LG; Poloz TL; Klimova OA; Gulyaeva LF; Zhimulev IF; Kolesnikov NN BMC Cancer; 2016 Mar; 16():201. PubMed ID: 26960768 [TBL] [Abstract][Full Text] [Related]
11. Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. Pallante P; Visone R; Croce CM; Fusco A Endocr Relat Cancer; 2010 Mar; 17(1):F91-104. PubMed ID: 19942715 [TBL] [Abstract][Full Text] [Related]
12. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer. Fuziwara CS; Saito KC; Kimura ET Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932 [No Abstract] [Full Text] [Related]
13. Clinical pathological impacts of microRNAs in papillary thyroid carcinoma: A crucial review. Chruścik A; Lam AK Exp Mol Pathol; 2015 Dec; 99(3):393-8. PubMed ID: 26321247 [TBL] [Abstract][Full Text] [Related]
14. TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells. Orlandella FM; Di Maro G; Ugolini C; Basolo F; Salvatore G Oncotarget; 2016 Oct; 7(43):70575-70588. PubMed ID: 27661106 [TBL] [Abstract][Full Text] [Related]
15. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790 [TBL] [Abstract][Full Text] [Related]
16. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Romei C; Ciampi R; Elisei R Nat Rev Endocrinol; 2016 Apr; 12(4):192-202. PubMed ID: 26868437 [TBL] [Abstract][Full Text] [Related]
17. Construction and investigation of lncRNA-associated ceRNA regulatory network in papillary thyroid cancer. Zhao Y; Wang H; Wu C; Yan M; Wu H; Wang J; Yang X; Shao Q Oncol Rep; 2018 Mar; 39(3):1197-1206. PubMed ID: 29328463 [TBL] [Abstract][Full Text] [Related]